Clot-busting drug for late back-of-brain strokes
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a clot-busting drug called tenecteplase for people who had a stroke in the back of the brain and arrive at the hospital within 4.5 to 24 hours of symptoms. It aims to see if giving this drug later than usual can improve recovery and reduce disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your stroke must have started between 4.5 and 24 hours ago (or you woke up with symptoms and the midpoint of that time fits).
- You must have had no major disability before the stroke (able to walk and care for yourself).
- A brain scan must show the stroke is in the back part of the brain (posterior circulation) and its size is not too large.
- Your blood pressure, blood sugar, and bleeding risk must be within safe limits for a clot-busting drug.
- You cannot be pregnant or nursing, and must agree to use birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.
This trial tests a clot-busting drug called tenecteplase given later than usual (4.5 to 9 hours after stroke symptoms) to people whose MRI shows the stroke may still be reversible. The goal is to see if it helps reduce disability after a stroke.
This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
Hear when a new Stroke Ischemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.